4P Pharma

4Moving Biotech announces the closing of a €12 million financing to advance a first-in-class DMOAD in knee osteoarthritis

Emmanuel DADJE — Tue, 10 Feb 2026 06:39:58 +0000

4Moving Biotech (4MB), a clinical stage biotechnology company developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today announces the closing of a €12 million financing, completed through a structured and coordinated funding process.

This financing was secured from a pool of private investors and family offices, who have chosen to reinforce their commitment by investing directly at the subsidiary level into 4Moving Biotech. The round includes a combination of equity and loans, reflecting a flexible capital structure aligned with long-term value creation.

A post 4Moving Biotech announces the closing of a €12 million financing to advance a first-in-class DMOAD in knee osteoarthritis from 4P Pharma.

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics

Emmanuel DADJE — Thu, 08 Jan 2026 06:39:53 +0000

We are pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for 4P004, developed by 4Moving Biotech, a subsidiary of 4P-Pharma. This authorization enables the initiation of clinical trial sites in the United States as part of the Phase 2a INFLAM-MOTION study. This important milestone supports the global rollout of the clinical program across Europe, Canada, and&hellip

A post 4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics from 4P Pharma.

HAPPY NEW YEAR 2026

Emmanuel DADJE — Tue, 06 Jan 2026 07:10:55 +0000

Since the early days of 4P-Pharma, we have gone through many stages of growth, each driven by the same ambition: to reach our vision of becoming a committed biotech-pharma company. Today, we hold an invaluable foundation in our hands: 👉 dedicated and talented people, 👉 strong and validated assets, 👉 a structured and resilient organization,&hellip

A post HAPPY NEW YEAR 2026 from 4P Pharma.

4P-Pharma at the 3rd Paris Digital Science & Innovation Day

Emmanuel DADJE — Wed, 12 Nov 2025 11:34:06 +0000

4P-Pharma is excited to take the stage at the 3rd Annual Paris Digital Science & Innovation Day, hosted by Benchling, on 18 November at Les Salons Hoche, Paris! 🇫🇷

Our CEO, Revital Rattenbach, will share how AI is ushering in a new era of virtual drug development, transforming how we generate evidence and design clinical studies, including:

✔️ How AI-driven patient stratification and virtual control arms are improving trial efficiency and reducing patient burden
✔️ How hybrid virtual trials inform study design before human execution, increasing the chances of success from the start
✔️ The future of virtual efficacy evaluation, where targeted real-world validation accelerates access and reduces costs

Join 200+ R&D leaders, scientists, and innovators to explore how AI, data, and digital transformation are redefining the future of biopharma.

A post 4P-Pharma at the 3rd Paris Digital Science & Innovation Day from 4P Pharma.

4P-Pharma at CPHI Frankfurt 2025

Emmanuel DADJE — Thu, 09 Oct 2025 15:21:39 +0000

We’re excited to announce that 4P-Pharma will be attending CPHI Frankfurt 2025 🇩🇪 Our Business Development team, Roselina Lam, Anne-Claire Gaudiez and our CMC expert, Frédéric Lallemand, will be on site to meet partners and explore new opportunities to accelerate access to treatments for patients. They look forward to connecting with you and discussing how we can&hellip

A post 4P-Pharma at CPHI Frankfurt 2025 from 4P Pharma.

First Patient Enrolled in the Phase 2a Clinical Trial, INFLAM MOTION

Emmanuel DADJE — Wed, 16 Jul 2025 13:36:53 +0000

We are delighted to share that 4Moving Biotech, a spin-off of 4P-Pharma, has enrolled the first patient in its Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, a first-in-class intra-articular GLP-1 therapy, in 129 patients with knee osteoarthritis (OA) across Europe and North America. We extend our sincere thanks to all partners, investigators, and patients who made this milestone possible. 👉&hellip

A post First Patient Enrolled in the Phase 2a Clinical Trial, INFLAM MOTION from 4P Pharma.

Be a boss Women Tour

Emmanuel DADJE — Wed, 28 May 2025 12:59:14 +0000

Revital Rattenbach, CEO de 4P-Pharma, a eu l’honneur d’être Marraine de l’étape lilloise du Be a boss Women Tour, le forum dédié aux femmes entrepreneures.

À cette occasion, elle a partagé son parcours, ses convictions et son engagement en tant qu’entrepreneure dans le domaine de la santé, devant un public de participants inspirés et inspirants.

A post Be a boss Women Tour from 4P Pharma.

4P-Pharma joins France Deeptech

Emmanuel DADJE — Tue, 05 Nov 2024 14:47:37 +0000

We are proud to announce that 4P-Pharma is joining the France Deeptech community. This initiative brings together key players in deeptech to provide an entrepreneurial, collective, and scientific response to contemporary challenges. By joining France Deeptech, 4P-Pharma strengthens its commitment to innovation in healthcare and continues its mission to deliver new and ambitious therapeutic solutions,&hellip

A post 4P-Pharma joins France Deeptech from 4P Pharma.

4P-Pharma welcomes Marina Vasiliou, Christian Bechon, and Alain Sainsot as independent members of its Board

Emmanuel DADJE — Tue, 10 Sep 2024 05:31:44 +0000

Lille & Paris, September 10th, 2024 – 4P-Pharma, a clinical-stage startup based in Lille that develops disease-modifying therapies for untreated serious diseases, is delighted to welcome Marina Vasiliou, Christian Bechon, and Alain Sainsot as independent and non-executive members to its Board of Directors. These novel additions will strengthen 4P-Pharma’s goal to become a commercial-stage, fully&hellip

A post 4P-Pharma welcomes Marina Vasiliou, Christian Bechon, and Alain Sainsot as independent members of its Board from 4P Pharma.

4P-Pharma’s New R&D Booster

Emmanuel DADJE — Tue, 03 Sep 2024 07:22:43 +0000

We’re thrilled to announce the launch of Dev4All, 4P-Pharma’s new R&D booster. With a strong biotech foundation and over ten years of experience, we turn innovative ideas into clinical-stage candidates. To visit our website,click here

A post 4P-Pharma’s New R&D Booster from 4P Pharma.

Happy Birthday 4P-Pharma

Emmanuel DADJE — Sun, 25 Aug 2024 07:18:25 +0000

We celebrate the tenth anniversary of 4P-Pharma—a decade of success, innovation, and growth. Since our beginning, we have achieved many important milestones and turned our ideas into realities, thanks to the passion and determination of our team. A big thank you to our team for this tremendous accomplishment, let’s celebrate our ten years!

A post Happy Birthday 4P-Pharma from 4P Pharma.

4Moving Biotech Welcomes Luc Boblet as Chief Executive Officer

Emmanuel DADJE — Tue, 02 Jul 2024 06:06:49 +0000

4Moving Biotech, a subsidiary of 4P-Pharma, is pleased to announce Luc Boblet’s appointment as its new Chief Executive Officer. Luc is an experienced and passionate biotech entrepreneur with two decades of experience. His established track record speaks highly about his leadership and vision. His expertise will be a key asset to 4Moving Biotech and the&hellip

A post 4Moving Biotech Welcomes Luc Boblet as Chief Executive Officer from 4P Pharma.